Resources

Coulter Partners successfully completed a search assignment for Alltrna and is pleased to announce the placement of Dave Hava, Ph.D. as Chief Scientific Officer (CEO).

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the appointment of four world leading experts to its Scientific Advisory Board (SAB).

In this blog, Ivana Visnjic-Lynch, Marketing Manager at ZAGENO, discusses the race for breakthrough therapies and the need for  effective R&D spend management which enables technology to unlock the future.

Abzena has announced the expansion of our AbZelectPRO™ cell line development (CLD) platform with the launch of two next-gen Glutamine Synthetase (“GS”) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Victoria House, a newly restored Grade II listed building in London’s Bloomsbury Square, officially opened its doors yesterday (16 September) as a state-of-the-art life sciences hub.

Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of David Ellis, PhD, in the newly created position of VP, Regulatory Affairs, based in the USA.

Cell and Gene Therapy Catapult (CGT Catapult), is working with VascVersa to develop a test that predicts the clinical efficacy of its experimental cell therapy for ischaemic diseases. This test will be used as a qualified assay as part of the cell manufacturing process.

LBIC announces that its new space in the Apex facility has reached over 50% occupancy just six months after launch, with the addition of Bind Research, its first non-profit tenant, and Twig Bio, a sustainable biotech company.

RSSL, a leading Life Sciences Contract Research Organization (CRO) and ERBC, a specialist in preclinical research and regulatory studies, have announced a strategic partnership designed to deliver integrated, end-to-end drug development support for pharmaceutical and biotech clients worldwide.

Coulter Partners, the global expert in building leadership teams for Health, Science and Technology innovation businesses, is proud of the successful placement of Valerio Ferri as Chief Executive Officer (CEO) at ExoLab Italia.

In the last week, we have been hit by headlines that MSD plans to close its discovery research activities in London and that AstraZeneca is pausing investment due to the UK commercial environment and specifically in response to VPAG outcomes.

In this interview, we speak with Abby Clark, the BIA's Manufacturing Programme Manager, who shares her personal journey from a degree-level apprenticeship to a key policy role.

The global collaboration provides an integrated translational biology platform to accelerate the development of novel radiopharmaceuticals.

In this blog Albert Maguire - King, Media and Communications Executive at BIA, outlines and explores BIA's revolutionary LeaP program.

A London-based biotech firm that aims to improve infant health with its research into the microbiomes of breast milk has raised £2.5 million.

Logical Biological, biospecimen and critical raw material leader based at Discovery Park, and Bcell Design, pioneers in transgenic monoclonal antibody technology, today announced a long term strategic international partnership to deliver engineered disease state materials for diagnostic and research markets.

Coulter Partners successfully completed a search assignment for the Cell and Gene Therapy Catapult (CGT Catapult) and is pleased to announce the placement of Dr. Ed Samuel as Chief Operations Officer (COO).

Discovery Park, Kent’s thriving life science and innovation community, today welcomed eight promising cardiovascular and cardiometabolic health startups to its campus. The cohort are embarking on the ‘Discovery Spark’ business growth programme, championing and supporting early stage business working on innovations in heart health.

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its product offering, with the launch of the AAVX Total Capsid Quantification Kit and the AAV9 Total Capsid Quantification Kit.

Myricx Bio is pleased to announce the appointment of Jonathon Marks-Bluth, Ph.D., to its leadership team in the newly created position of VP, Business Development.